• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Sofinnova Partners S.A.S.

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Headquartered in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. *

 

	Start	1997-08-25 established
	Group	Sofinnova (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Papiernik, Antoine (Sofinnova Partners 201703 Managing Partner + Chairman joined 1997)
	Person 2	Lucquin, Denis (Sofinnova Partners 201509 Managing Partner + Chairman)
	Region	Paris
	Country	France
	Street	18 rue du 4 Septembre
	City	75002 Paris
		Address record changed: 2015-09-06
Basic data	Employees	B: 11 to 50 (2017-03-28)
	Currency	EUR
	Annual sales	2,000,000,000 (funds, managed (2019) 2019-10-17)
		* Document for �About Section�: Sofinnova Partners. (10/17/19). "Press Release: Sofinnova Partners Raises €333 Million Capital IX Early-stage Healthcare Fund". Paris.
		Record changed: 2019-10-19

Advertisement

More documents for Sofinnova (Group)

• [1] Sofinnova Partners. (10/17/19). "Press Release: Sofinnova Partners Raises €333 Million Capital IX Early-stage Healthcare Fund". Paris....
• [2] Microphyt. (7/11/19). "Press Release: Microphyt Raises €28.5 Million to Develop Its Portfolio of Microalgae-based Natural Solutions for Nutrition and Well-being". Baillargues....
• [3] Karuna Therapeutics, Inc.. (4/1/19). "Press Release: Karuna Completes $80 Million Series B Financing". Boston, MA....
• [4] Polyneuron Pharmaceuticals AG. (3/28/19). "Press Release: Polyneuron Raises CHF22.5 Million in Series A to Advance Novel Therapies for Autoimmune Diseases". Basel....
• [5] Rgenix, Inc.. (10/9/18). "Press Release: Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs". New York, NY....
• [6] HotSpot Therapeutics, Inc.. (7/17/18). "Press Release: HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discvovery". Cambridge, MA....
• [7] NodThera Ltd.. (6/25/18). "Press Release: NodThera Secures £28 Million ($40 Million) Series A Financing". Cambridge....
• [8] Sofinnova Partners. (5/21/18). "Press Release: Sofinnova Partners Appoints Dr. Martin T. Rothman as Venture Partner". Paris....
• [9] EryDel S.p.A.. (4/24/18). "Press Release: EryDel Raises Euro 26.5 Million in Financing. Sofinnova Partners Leads Erydel’s Financing". Bresso....
• [10] Sofinnova Partners. (4/23/18). "Press Release: Armance Bordes Joins Sofinnova Partners as General Counsel". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.